Results 251 to 260 of about 12,458,805 (285)

PHGDH drives 5-FU chemoresistance in colorectal cancer through the Hedgehog signaling. [PDF]

J Exp Clin Cancer Res
Mancini C, Lori G, Mattei G, Iozzo M, Desideri D, Cianchi F, Fortuna L, Passagnoli F, Massi D, Ugolini F, Messerini L, Piscuoglio S, Pezone A, Magherini F, Biagioni A, Lottini T, Zambardino D, Truglio GI, Petricci E, Magi A, Arcangeli A, Maresca L, Stecca B, Pranzini E, Taddei ML.   +24 more
europepmc   +1 more source

Development and Characterization of Optimized Drug-Loaded Niosomes for Delivery of 5-FU and Irinotecan. [PDF]

Pharmaceutics
Agbaje KO, Adesina SK, Adebayo AS.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres

International Journal of Pharmaceutics, 2004
The purpose of this study was to compare the combination (Paclitaxel + 5-FU microspheres) with a single drug chemotherapy (Paclitaxel and 5-FU microspheres) against metastatic breast cancer cell line (MDA-MB 435 S). The physicochemical characteristics of the microspheres (i.e.
Anshul, Gupte, Kadriye, Ciftci
openaire   +2 more sources

Effects of 5-FU

2010
5-fluorouracil (5-FU) is a chemotherapeutical agent used to treat cancers including breast and colorectal. Working as an antimetabolite to prevent cell proliferation, it primarily inhibits the enzyme thymidylate synthase blocking the thymidine formation required for DNA synthesis.
Peter M, Wigmore, Sarah, Mustafa, Maha, El-Beltagy, Laura, Lyons, Jariya, Umka, Geoff, Bennett   +5 more
openaire   +2 more sources

Conversion of a Nŏvel 5-Fluorouracil (5-FU) Derivative to 5-FU in Rats

Journal of Urology, 1983
The converting efficiency of a novel 5-FU derivative, 1, 3-didecanoyl-2-[6-[(5-fluorouracil-l-yl) carbonylamino] hexanoyl]glyceride (DFUG), to 5-FU was investigated in rat plasma. The degradation half-life of DFUG was 4.04 min when DFUG was incubated in rat plasma at 37 degrees C, though DFUG was considerably stable in buffers having different pH ...
K, Takada, H, Yoshikawa, S, Muranishi
openaire   +2 more sources

Cyclophosphamide plus 5-FU versus 5-FU Alone in Advanced Gastric Carcinoma

Oncology, 2009
30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2–5, beginning on day 8.
R T, Chlebowski, J M, Weiner, I, Silverberg, A, Glass, J R, Bateman   +4 more
openaire   +2 more sources

Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs

Journal of Pharmaceutical Sciences, 2003
The 3-alkylcarbonyloxymethyl-5-fluorouracil (3-ACOM-5-FU) prodrugs have been characterized by their solubilities in isopropyl myristate (S(IPM)) and partition coefficients between IPM and pH 4.0 buffer (K(IPM:AQ)). Estimated S(AQ) values have been obtained from S(AQ) = S(IPM)/K(IPM:AQ.) The abilities of the prodrugs to deliver total 5-FU species from ...
William J, Roberts, Kenneth B, Sloan
openaire   +2 more sources

Colorectal cancer—Is there an alternative to 5-FU?

European Journal of Cancer, 1997
info:eu-repo/semantics ...
openaire   +3 more sources